|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008972,
umls-concept:C0017431,
umls-concept:C0034656,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0683598,
umls-concept:C0936012,
umls-concept:C1442488,
umls-concept:C1456409,
umls-concept:C1511726,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2587213
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-2
|
|
pubmed:abstractText |
To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
503-14
|
|
pubmed:meshHeading |
pubmed-meshheading:20051805-Anti-HIV Agents,
pubmed-meshheading:20051805-Clinical Trials, Phase III as Topic,
pubmed-meshheading:20051805-Disease Susceptibility,
pubmed-meshheading:20051805-Drug Resistance, Viral,
pubmed-meshheading:20051805-Genotype,
pubmed-meshheading:20051805-HIV Infections,
pubmed-meshheading:20051805-HIV-1,
pubmed-meshheading:20051805-Humans,
pubmed-meshheading:20051805-Mutation,
pubmed-meshheading:20051805-Phenotype,
pubmed-meshheading:20051805-Pyridazines,
pubmed-meshheading:20051805-Randomized Controlled Trials as Topic,
pubmed-meshheading:20051805-Treatment Outcome,
pubmed-meshheading:20051805-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
|
|
pubmed:affiliation |
Tibotec BVBA, Gen De Wittelaan L 11B 3, Mechelen, Belgium. JVINGERH@its.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
